Paper Details

  1. Home
  2. Paper Details

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Author: Abdel-WahabOmar, AlbackerLee A, AliSiraj, ArcilaMaria, BenayedRyma, BitnerLillian, ChungStephen S, ChungYoung Rock, CoccoEmiliano, DiamondEli L, DurhamBenjamin H, EbataKevin, HechtmanJaclyn F, HymanDavid M, InoueDaichi, KuNora, MarcelusChristina, MughalTariq I, MullaneyKerry, ParkJae H, PavlickDean, RoshalMikhail, ScaltritiMaurizio, TaylorJustin, TuchBrian B, WattsJustin M, YoshimiAkihide

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

TRK fusions, while rare, are present in a variety of hematologic malignancies and confer responsiveness to TRK inhibition. This suggests that TRK inhibition may be a viable therapeutic option for these patients.
Paper Details　
Original Abstract of the Article :
Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profoun...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118587/

データ提供：米国国立医学図書館（NLM）

TRK Fusions: A New Target for Treatment in Hematologic Malignancies

This study examines the potential of targeting TRK fusions, oncogenic rearrangements in neurotrophic receptor kinase genes, for the treatment of hematologic malignancies. It explores the frequency of TRK fusions across a large dataset of hematologic malignancies and investigates their clinical implications. The study identifies TRK fusions in various hematologic malignancies, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma. The study demonstrates the sensitivity of these TRK fusions to TRK inhibitors, both in vitro and in vivo, suggesting a potential therapeutic target for these malignancies.

TRK Fusions: A Promising Target for Hematologic Cancers

This research identifies TRK fusions as a potential therapeutic target for a wide range of hematologic malignancies. The study demonstrates the sensitivity of these fusions to TRK inhibitors, providing a potential pathway for developing effective treatments for these cancers. These findings hold promise for improving patient outcomes and extending their lifespans.

Expanding Our Horizons in Cancer Treatment

This research showcases the importance of ongoing research and innovation in cancer treatment. Just as a camel adapts to changing desert conditions, we must constantly adapt and evolve our approaches to treating cancer. The discovery of TRK fusions as a potential therapeutic target opens exciting new avenues for developing effective treatments and improving patient outcomes.

Dr.Camel's Conclusion

This research provides a promising new avenue for the treatment of hematologic malignancies. The identification of TRK fusions as a potential therapeutic target holds great promise for the development of effective treatments and improving patient outcomes. The fight against cancer is a continuous journey, and this discovery represents a significant stride forward in our quest to conquer this disease.

Date :
  1. Date Completed 2019-09-24
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

29920189

DOI: Digital Object Identifier

PMC6118587

Related Literature

Article Analysis
・Effects of larotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.